Cancer immunotherapy |
Naked monoclonal antibodies |
Alemtuzumab is used to treat some patients suffering from Chronic Lymphocytic leukemia |
Conjugated antibodies |
Brentuximab vedotin binds to CD30 antigen, used against Hodgkin’s lymphoma |
Bispecific monoclonal antibodies |
Blinatumomab, whose one half binds to CD19 and the other half binds to CD3, used to treat acute lymphocytic leukemia |
Immune checkpoint inhibitors |
Monoclonal antibody blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) with ipilimumab |
Non-specific immunotherapy |
Some interleukins and interferons are used |
• IFN-α for use against hairy cell leukemia; |
• IL-2 is approved to treat advanced kidney cancer and metastatic melanoma |
Targeted vaccine therapy |
Sipuleucel-T (Provenge) is a dendritic cell vaccine, used to treat advanced prostate cancer |
• Tumor cell vaccine |
• Antigen vaccine |
• Peptide-based vaccine |
• DNA-based vaccine |
• Dendritic cell vaccine |